Thought organization
Thought organization (also known as fluid intelligence)[1] is defined as a state of mind in which one's ability to analyze and categorize conceptual information using a systematic and logical thought process is considerably increased.[2][3][4] It seemingly occurs through reducing thoughts which are unrelated or irrelevant to the topic at hand, therefore improving one's capacity for a structured and cohesive thought stream.[2][5] This effect also seems to allow the person to hold a greater amount of relevant information (as evidenced by language comprehension increases)[4] in their train of thought which can be useful for extended mental calculations, articulating ideas, and analyzing logical arguments.
Thought organization is often accompanied by other coinciding effects such as analysis enhancement and thought connectivity. It is most commonly induced under the influence of mild dosages of stimulant and nootropic compounds, such as amphetamine, methylphenidate, and Noopept. However, this effect can occur to a lesser extent under the influence of certain cannabis strains and spontaneously during psychedelic states. It is also worth noting that the same compounds which induce this mind state at light to moderate dosages can often result in the opposite effect of thought disorganization at heavier dosages.[3][5][6]
Psychoactive substances
Compounds within our psychoactive substance index which may cause this effect include:
- 2-FA
- 2-FEA
- 2-FMA
- 3,4-CTMP
- 4-AcO-DMT
- 4F-MPH
- Amphetamine
- Armodafinil
- Ayahuasca
- Cocaine
- Creatine
- Cyclazodone
- DMT
- Desoxypipradrol
- ETH-CAT
- ETH-LAD
- Ibogaine
- Lisdexamfetamine
- MDPV
- Methamphetamine
- Methiopropamine
- Methylphenidate
- Prolintane
- Propylhexedrine
- Psilocin
- Psilocybin mushrooms
- SAM-e
- Theanine
Experience reports
Annectdotal reports which describe this effect with our experience index include:
- Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis
- Experience:100-350mg - Phenylpiracetam in daily life
- Experience:2.5g Psilocybe Cubensis B+ strain - epiphany of nondualistic reality
- Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
- Experience:BK-2C-B - Various experiences
- Experience:FMA (37.5 mg, oral) - Never been this productive in my life
- Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
See also
- Responsible use
- Subjective effects index
- Thought disorganization
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
External links
References
- ↑ Diamond, Adele (2013). "Executive Functions". Annual Review of Psychology. 64 (1): 135–168. doi:10.1146/annurev-psych-113011-143750. ISSN 0066-4308.
- ↑ 2.0 2.1 Biederman, Joseph; Seidman, Larry J.; Petty, Carter R.; Fried, Ronna; Doyle, Alysa E.; Cohen, Daniel R.; Kenealy, Deborah C.; Faraone, Stephen V. (2008). "Effects of Stimulant Medication on Neuropsychological Functioning in Young Adults With Attention-Deficit/Hyperactivity Disorder". The Journal of Clinical Psychiatry. 69 (7): 1150–1156. doi:10.4088/JCP.v69n0715. ISSN 0160-6689.
- ↑ 3.0 3.1 Gupta, B.S. (1977). "Dextroamphetamine and measures of intelligence". Intelligence. 1 (3): 274–280. doi:10.1016/0160-2896(77)90010-1. ISSN 0160-2896.
- ↑ 4.0 4.1 Hellwig-Brida, Susanne; Daseking, Monika; Keller, Ferdinand; Petermann, Franz; Goldbeck, Lutz (2011). "Effects of Methylphenidate on Intelligence and Attention Components in Boys with Attention-Deficit/Hyperactivity Disorder". Journal of Child and Adolescent Psychopharmacology. 21 (3): 245–253. doi:10.1089/cap.2010.0041. ISSN 1044-5463.
- ↑ 5.0 5.1 Arnsten, Amy F.T.; Li, Bao-Ming (2005). "Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions". Biological Psychiatry. 57 (11): 1377–1384. doi:10.1016/j.biopsych.2004.08.019. ISSN 0006-3223.
- ↑ Lundqvist, T (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions". Pharmacology Biochemistry and Behavior. 81 (2): 319–330. doi:10.1016/j.pbb.2005.02.017. ISSN 0091-3057.